Determination of Low Level Sulfides in Environmental Waters by Automated Gas Dialysis/Methylene Blue Colorimetry

Abstract

A sensitive and rapid automated method has been developed for the selective analysis of acid extractable sulfide in environmental samples by combining gas dialysis separation techniques with methylene blue detection procedures. Acid extractable sulfide is separated from the sample matrix by the gas dialysis membrane and subsequently trapped in a dilute sodium hydroxide receiving stream. This stream is reacted with N, N-dimethyl-p-phenylenediamine and ferric chloride to produce methylene blue which is then quantitated colorimetrically at 660 nm. For standards and nonturbid environmental samples, there is good agreement between the results obtained by this procedure and the standard methylene blue method. The effect of interferences on the accurate determination of sulfide by both methods was also examined and it was found that cupric ions significantly interfered with sulfide estimation. To obtain adequate sulfide recoveries in tap water and environmental samples ascorbic acid must be added as an antioxidant. A detection limit of 2 μg/L of sulfide has been obtained using this procedure.     

Pre- and post-dialysis quantitative dosage of thymidine in urine and plasma of a MNGIE patient by using HPLC-ESI-MS/MS

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder characterized by severe gastrointestinal dysmotility, cachexia, ptosis, ophthalmoparesis, peripheral neuropathy and leukoencephalopathy. The disease is due to a thymidine phosphorylase defect. This enzyme catalyses the phosphorolysis of thymidine to thymine and deoxyribose 1-phosphate. For this reason, increased levels of thymidine in plasma and urine are found in MNGIE patients. Haemodialysis can reduce circulating plasma thymidine levels and can be beneficial in some MNGIE patients. We developed a fast analytical method based on HPLC-ESI-MS/MS capable of identifying pyrimidine nucleotides (thymine, cytosine, uracil) and nucleosides (thymidine, citidine, uridine) in plasma and urine after direct dilution of the samples without pre-treatment. In the patient studied, we observed a significant reduction of plasmatic and urinary thymidine levels during and after dialysis. However, we noted a progressive reduction of the initial thymidine level after some dialytic trials. This method will be useful not only for thymidine level follow-up during dialysis in MNGIE patients but also for the improvement of the diagnosis or diagnostic suspect in other pyrimidine defects such as dihydropyrimidine dehydrogenase deficiency, dihydropyrimidinase deficiency and ureidopropionase deficiency.